All News

Zydus Pharmaceuticals (USA) Inc,. has come a long way since its first commercial launch in August 2005.

Pharmacy technicians should advocate for fair pay raises due to their crucial role, expanding skills, and cost-effectiveness over turnover.

On this episode, guests discuss how pharmacists can advocate for policy changes at the state level.

Sleep loss is known to impact key processes such as attention, cognition, learning, memory, metabolism, and immune function.

Researchers sought to find a remedy for the development of treatment-resistant depression in patients whose antidepressant treatment has fluctuated in efficacy.

The treatment is the first of its kind to be FDA-approved to treat CHAPLE disease.

“I've never met a pharmacist who didn't want to improve the health of the American people. That's what they're doing and will be doing well in the future,” Steven C. Anderson tells Pharmacy Times at NACDS TSE, August 12 through 14, 2023, San Diego, California.

Most participants who received retatrutide lost a considerable amount of body weight; however, individual results varied given the diversity of obesity.

August's Condition Watch focuses on skin health.

Multiple requests for delays had been submitted.

This month, we spoke with Cassia Griswold, PharmD, a clinical oncology pharmacist at Mayo Clinic Arizona.

The model was the first to incorporate C-reactive protein/albumin ratio and apply LASSO regression analysis to a predictive model for children with Kawasaki disease.

The results differ from previous studies and the predictions of the researchers that the Child Tax Credit would reduce the prevalence of low birth weight among pregnant women across the country.

Pharmacists can offer valuable information about sunburn, sunscreen, and skin cancer screening and provide OTC recommendations on sunburn treatment and prevention.

Opportunities for an additional specialization in molecular pathology may be helpful to train professionals in the real-time interpretation of gene therapy test results.

This months generic product news includes azithromycin tablets, minocycline hydrochloride tablets, carboprost tromethanmine injection, and tadalafil tablets.

Guidelines from the American Academy of Pediatrics recommend treating obesity as a chronic illness.

Based on results from a trial of repotrectinib in patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer, the FDA accepted the New Drug Application and set a Prescription Drug User Fee Act goal date of November 27, 2023.

The approach allows investigators to assess post-vaccine response in immunocompromised patients who have received antibody prophylaxis.

Previous studies have shown promising results with liver or kidney transplants in patients with HIV, but there was a lack of literature regarding heart transplants specifically.

Although the rate of people with probable insomnia who discussed their sleep habits with a physician was relatively high, the number of people who went on to seek actual treatment was low.

Annual NCODA Oncology Institute brings together leaders in industry to speak with leaders in clinical practice to discuss some of the commonalities and areas of opportunity to address challenges facing oncology professionals.

The law has impacted the number of physicians receiving payment from drug companies.

Experts Christina Madison, PharmD, FCCP, AAHIVP, and Joy Hoover, founder of Esōes Cosmetics, sat down to discuss how cosmetics can empower users of all genders.

Adjustments for social determinants of health in the US population had a significant impact on cardiovascular disease mortality data between Black and White populations.

The findings of the study demonstrate the need for preventive interventions for all infants in order to reduce the burden of severe illness from respiratory syncytial virus lower respiratory tract infections.

A COVID-19 booster dose increased both maternal and cord blood binding and neutralizing antibody levels against virus strains, including Omicron BA.1.

The Mylight phase 3 trial confirmed that there was no clinically meaningful differences between aflibercept and its reference biologic, Eylea, for patients with wet macular degeneration.

The combination regimen showed positive progression-free survival results among patients with HER2-positive breast cancer in the phase 3 HER2CLIMB-02 trial, but overall survival data have yet to mature.